Abstract：
BACKGROUND: Hand-foot-mouth is a viral infectious disease characterized by fever, hand foot rash and oral mucosal herpes caused by a variety of enteroviruses. It is often found in preschool children, and its immune system is not well developed, so it is very susceptible to infection by pathogens and epidemics, resulting in rapid progress of the disease. At present, the commonly used Chinese patent medicine oral liquid in our country has good clinical efficacy of antiviral, antibacterial, antiphlogistic and improving immunity, but there is no evidence to compare the clinical efficacy and safety of a variety of oral liquid of Chinese patent medicine. Therefore, this study is aim to use the network meta-analysis to integrate the clinical relevant evidence of direct and indirect comparative relationship, and to conduct quantitative comprehensive statistical analysis and sequencing after the aggregation of different Chinese patent medicine oral liquid with the same evidence body, and then the best clinical medication scheme is selected, which can provide reference value and evidence-based theoretical evidence for clinical optimization of drug selection.
METHODS: Comprehensive retrieval of CNKI, VIP, CBM, and WANFANG database and the Cochrane Library, PubMed, Web of Science and EMBASE database. Search and publish the clinical RCT of these 7 kinds of oral liquid of Chinese patent medicine compared with ribavirin or oral liquid of Chinese patent medicine. The retrieval time is from the establishment of the database to October 31st, 2021. The 2 first authors will screen the literatures that meets the inclusion criteria, extract the data independently according to the predesigned rules, and evaluate the literature quality and bias risk of the included research according to the Cochrane manual standard. Data merging and network meta-analysis were carried out with R programming software to evaluate the ranking probability of all interventions.
RESULTS: This network meta-analysis and probability ranking will identify the best Chinese patent medicine oral liquid treatment for Hand-foot-mouth.
CONCLUSIONS: This study will provide systematic evidence-based medicine evidence for Chinese patent medicine oral liquid treatment for Hand-foot-mouth, and help clinicians, patients with poststroke depression and decision-makers to make more effective, safer and economic optimal treatment plan in the decision-making process.
BACKGROUND: INPLASY202210032. The protocol for this systematic review was registered on INPLASY and is available in full on the inplasy.com (https://inplasy.com/inplasy-2022-1-0032/).
METHODS: Comprehensive retrieval of CNKI, VIP, CBM, and WANFANG database and the Cochrane Library, PubMed, Web of Science and EMBASE database. Search and publish the clinical RCT of these 7 kinds of oral liquid of Chinese patent medicine compared with ribavirin or oral liquid of Chinese patent medicine. The retrieval time is from the establishment of the database to October 31st, 2021. The 2 first authors will screen the literatures that meets the inclusion criteria, extract the data independently according to the predesigned rules, and evaluate the literature quality and bias risk of the included research according to the Cochrane manual standard. Data merging and network meta-analysis were carried out with R programming software to evaluate the ranking probability of all interventions.
RESULTS: This network meta-analysis and probability ranking will identify the best Chinese patent medicine oral liquid treatment for Hand-foot-mouth.
CONCLUSIONS: This study will provide systematic evidence-based medicine evidence for Chinese patent medicine oral liquid treatment for Hand-foot-mouth, and help clinicians, patients with poststroke depression and decision-makers to make more effective, safer and economic optimal treatment plan in the decision-making process.
BACKGROUND: INPLASY202210032. The protocol for this systematic review was registered on INPLASY and is available in full on the inplasy.com (https://inplasy.com/inplasy-2022-1-0032/).
摘要：
背景：手足口病是一种以发热为特征的病毒性传染病，由多种肠道病毒引起的手足皮疹和口腔黏膜疱疹。它常见于学龄前儿童，它的免疫系统也不发达，所以它很容易被病原体和流行病感染，导致疾病的快速进展。目前,我国常用的中成药口服液具有良好的抗病毒临床疗效,抗菌，消炎和提高免疫力，但没有证据比较多种中成药口服液的临床疗效和安全性。因此,本研究旨在使用网络荟萃分析整合直接和间接比较关系的临床相关证据，用同一证据体聚集不同中成药口服液后进行定量综合统计分析和测序，然后选择最佳的临床用药方案，为临床优化药物选择提供参考价值和循证理论依据。
方法：CNKI综合检索，VIP,CBM,WANFANG数据库和Cochrane图书馆，PubMed,WebofScience和EMBASE数据库。检索并公布这7种中成药口服液与利巴韦林或中成药口服液的临床RCT。检索时间是从建立数据库到10月31日,2021年。两位第一作者将筛选符合纳入标准的文献，根据预先设计的规则独立提取数据，并根据Cochrane手册标准评估纳入研究的文献质量和偏倚风险。使用R编程软件进行数据合并和网络荟萃分析，以评估所有干预措施的排名概率。
结果：该网络荟萃分析和概率排名将确定最佳的中成药口服液治疗手足口病。
结论：本研究将为中成药口服液治疗手足口病提供系统的循证医学证据。帮助临床医生，卒中后抑郁患者和决策者更有效，决策过程中更安全、经济的最优治疗方案。
背景：INPLASY202210032。本系统审查的协议已在INPLASY上注册，并可在inplasy.com（https://inplasy.com/inplasy-2022-1-0032/）上获得。
方法：CNKI综合检索，VIP,CBM,WANFANG数据库和Cochrane图书馆，PubMed,WebofScience和EMBASE数据库。检索并公布这7种中成药口服液与利巴韦林或中成药口服液的临床RCT。检索时间是从建立数据库到10月31日,2021年。两位第一作者将筛选符合纳入标准的文献，根据预先设计的规则独立提取数据，并根据Cochrane手册标准评估纳入研究的文献质量和偏倚风险。使用R编程软件进行数据合并和网络荟萃分析，以评估所有干预措施的排名概率。
结果：该网络荟萃分析和概率排名将确定最佳的中成药口服液治疗手足口病。
结论：本研究将为中成药口服液治疗手足口病提供系统的循证医学证据。帮助临床医生，卒中后抑郁患者和决策者更有效，决策过程中更安全、经济的最优治疗方案。
背景：INPLASY202210032。本系统审查的协议已在INPLASY上注册，并可在inplasy.com（https://inplasy.com/inplasy-2022-1-0032/）上获得。
